13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01337986
(ClinicalTrials.gov)
May 201113/4/2011Ampyra for Optic Neuritis in Multiple SclerosisDalfampridine After Optic Neuritis to Improve Visual Function in Multiple SclerosisMultiple Sclerosis;Optic NeuritisDrug: Dalfampridine/Placebo;Drug: Placebo/DalfampridineWashington University School of MedicineAcorda TherapeuticsCompleted18 Years55 YearsAll53Phase 2;Phase 3United States
2EUCTR2010-023678-38-IT
(EUCTR)
20/04/201102/02/2011High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - NDHigh-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND patients with multiple sclerosis
MedDRA version: 9.1;Level: PT;Classification code 10028245
Trade Name: MANTADAN*20CPR 100MG
INN or Proposed INN: Amantadine
Trade Name: AMPYRA
INN or Proposed INN: Ampyra
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABORNULLNot RecruitingFemale: yes
Male: yes
Italy